Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHG Pharmaceutical JSCSTC:DHG 78 5-Year Yield-on-Cost % is 10.50 as of Jul. 17, 2026, which is 46% above its 10-year median of 7.17. GuruFocus rates STC:DHG with a GF Score™ of 78/100 and a GF Value™ of ₫113,872.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 514 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 90.27% on this metric.
DHG Pharmaceutical JSC's yield on cost for the quarter that ended in Mar. 2026 was 10.50.
The historical rank and industry rank for DHG Pharmaceutical JSC's 5-Year Yield-on-Cost % or its related term are showing as below:
STC:DHG'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.44 Med: 7.17 Max: 25.93
Current: 10.5
During the past 13 years, DHG Pharmaceutical JSC's highest Yield on Cost was 25.93. The lowest was 2.44. And the median was 7.17.
STC:DHG's 5-Year Yield-on-Cost % is ranked better than 90.27% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs STC:DHG: 10.50
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
DHG Pharmaceutical JSC 5-Year Yield-on-Cost % Related Terms
STC:DHG vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
DHG Pharmaceutical JSC (STC:DHG) has a 5-Year Yield-on-Cost % of 10.50 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DHG Pharmaceutical JSC and its competitors. This is 46% above median its historical median of 7.17. Over the past decade, DHG Pharmaceutical JSC's 5-Year Yield-on-Cost % has ranged from 2.44 to 25.93. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #50 out of 514 companies in the Drug Manufacturers industry, placing it in the top 9.7%.
Is DHG Pharmaceutical JSC's 5-Year Yield-on-Cost % too high?
DHG Pharmaceutical JSC's current 5-Year Yield-on-Cost % of 10.50 is 46% above median its 10-year median of 7.17. Over the past 10 years, this metric has ranged from a low of 2.44 to a high of 25.93. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.33. DHG Pharmaceutical JSC's value of 10.50 is 351.6% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #50 out of 514 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #50 out of 514 companies for 5-Year Yield-on-Cost %. This places DHG Pharmaceutical JSC in the top 10% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.33. DHG Pharmaceutical JSC's value of 10.50 is 351.6% above this benchmark. Historically, DHG Pharmaceutical JSC's own 5-Year Yield-on-Cost % has ranged from 2.44 to 25.93 over the past decade. While the company's 10-year median is 7.17 vs. the industry median of 2.33, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.33, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current 5-Year Yield-on-Cost % of 10.50 is 351.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current 5-Year Yield-on-Cost % is 10.50, which is 46% above median its own 10-year median of 7.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,872.18, compared to a current price of ₫92,200.00 — trading 19% below its estimated fair value. The current 5-Year Yield-on-Cost % is 10.50, which is 46% above median its 10-year median of 7.17 and 351.6% above the Drug Manufacturers industry median of 2.33. DHG Pharmaceutical JSC's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current 5-Year Yield-on-Cost % is 10.50 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫92,200.00 is trading 19% below its estimated GF Value™ of ₫113,872.18.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
5-Year Yield-on-Cost %: 10.50 (46% above median its 10-year median of 7.17)
GF Value™: ₫113,872.18 vs. price of ₫92,200.00 (19% below fair value)
Industry Position: 351.6% above the Drug Manufacturers median (#50 of 514)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
78GF Score
Get the complete analysis for STC:DHG
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
